GlassScriptPhysician profile
Richard P Levy
NPI 1811245533
$2,660.49
in general payments reported to CMS, 2019-2025
37 companies · $1,123 in 2025
The $1,123 reported for 2025 was more than what 85% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $81.43 · 2020: $13.76 · 2021: $97.45 · 2022: $106 · 2023: $803 · 2024: $435 · 2025: $1,123.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,361.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,361.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $366.05 | 2022-2025 | Rybrevant, Carvykti, Darzalex |
| Glaxosmithkline, LLC. | $298.74 | 2023-2025 | Ojjaara |
| Genzyme Corporation | $196.71 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $149.80 | 2025 | |
| Lilly USA, LLC | $142.84 | 2020-2025 | Jaypirca, Verzenio, Retevmo |
| Merck Sharp & Dohme LLC | $138.18 | 2023-2025 | Keytruda, Keytruda Qlex |
| Blue Earth Diagnostics | $112.86 | 2022-2025 | Posluma |
| Takeda Pharmaceuticals U.S.A., INC. | $102.58 | 2023-2024 | Ninlaro, Iclusig |
| Bayer Healthcare Pharmaceuticals INC. | $97.49 | 2019-2024 | |
| Gilead Sciences, INC. | $82.61 | 2023 | Trodelvy |
| Varian Medical Systems, INC. | $59.20 | 2019 | |
| Tactile Systems Technology INC | $56.89 | 2025 | Flexitouch Plus, Nimbl |
| Pharmacosmos Therapeutics INC. | $55.84 | 2025 | Monoferric |
| Abbvie INC. | $53.51 | 2025 | |
| Myovant Sciences INC. | $49.98 | 2021 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $48.02 | 2025 | Libtayo |
| Seagen INC. | $47.77 | 2023 | Adcetris |
| Incyte Corporation | $46.78 | 2023-2025 | Jakafi |
| Pfizer INC. | $45.23 | 2025 | |
| Emd Serono, INC. | $43.39 | 2025 | |
| Progenics Pharmaceuticals, INC. | $41.85 | 2023 | Pylarify |
| Amgen INC. | $37.03 | 2023 | Lumakras, Kyprolis |
| Aveo Pharmaceuticals, INC. | $34.99 | 2023-2025 | Fotivda |
| Astrazeneca Pharmaceuticals LP | $33.78 | 2023-2025 | Imfinzi, Lynparza |
| Karyopharm Therapeutics INC. | $31.59 | 2025 | Xpovio |
| Jazz Pharmaceuticals INC. | $31.36 | 2023 | Zepzelca |
| Celgene Corporation | $29.77 | 2025 | Opdivo |
| Accuray Incorporated | $26.17 | 2025 | |
| Myriad Genetic Laboratories, INC. | $25.51 | 2023 | Myrisk |
| Adaptive Biotechnologies Corporation | $25.28 | 2023 | Clonoseq |
| Stemline Therapeutics INC. | $25.15 | 2023 | Orserdu |
| Daiichi Sankyo INC. | $25.10 | 2023 | Injectafer |
| Novocure INC. | $24.35 | 2021 | |
| Menarini Silicon Biosystems, INC. | $22.97 | 2024 | |
| Beigene USA, INC. | $21.67 | 2024 | Brukinsa |
| Coherus Oncology, INC. | $15.09 | 2024 | |
| Eisai INC. | $14.36 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Levy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.